The Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND trial is a multicentre, open-label, single and multiple dose-escalation and pharmacokinetic study of Cu(II)ATSM to determine the recommended phase 2 dose.
The Principal Investigator is Professor Matthew Kiernan, Sydney Neurology. Recruitment is expected to commence in the next few months* for individuals who meet specific inclusion criteria. For detailed information including recruitment and exclusion criteria see https://clinicaltrials.gov/ct2/show/NCT02870634. For more general information for people considering participating in research see here.
*STOP PRESS: As at September 2016 we have been advised that it is now likely that this trial won't commence until March 2017.